Outset Medical, Inc. (NASDAQ: OM)

Outset is a medical technology company pioneering a first of its kind technology to improve clinical outcomes in dialysis with less cost and complexity. The company's flagship product, the Tablo Hemodialysis System, integrates water purification, on demand dialysate production, and data connectivity into a single compact console. Designed for use across hospital, clinic, and home settings, Tablo enables dialysis delivery anytime, anywhere, and by virtually any trained user. The Tablo system has received clearance from the U. S. Food and Drug Administration for use in hospital, clinic, and home settings, underscoring its regulatory compliance and readiness for broad adoption.

Outset generates revenue primarily from the sale of Tablo consoles and the recurring sale of disposable cartridges required for each treatment. The company also offers service contracts, training programs, and data analytics subscriptions that support the Tablo ecosystem. Its customers are dialysis providers, including hospitals, outpatient clinics, skilled nursing facilities, and home care programs, who purchase or lease the system to deliver therapy to patients. Service revenue includes field support, remote monitoring, and preventive maintenance, which are delivered through the company’s dedicated service team. Outset sells its products directly to dialysis providers and also works with distribution partners to expand its reach.

Outset competes in the dialysis equipment market against established players such as Fresenius Medical Care, DaVita (through its Mozarc joint venture), B. Braun, and Quanta Dialysis Technologies. Its competitive advantage lies in offering a single platform that can be used in acute, chronic, and home environments, reducing the need for multiple machines and associated infrastructure. The system’s ease of use, shortened setup time, and integrated data analytics capabilities further differentiate it from traditional dialysis equipment. Clinical studies have shown that Tablo reduces treatment setup time from approximately 45 minutes to under 20 minutes, contributing to greater staff efficiency. The platform’s integrated cloud connectivity enables real time device monitoring, predictive maintenance, and automated documentation, which lowers operational costs for providers.

Outset serves a broad range of dialysis providers, including acute care hospitals, chronic dialysis clinics, skilled nursing facilities, long term acute care hospitals, and home based patients. While the filing does not disclose specific customer names, the company notes that it has worked with nearly 1,000 acute care facilities to support insourced dialysis programs. The company’s recurring revenue depends on the ongoing purchase of cartridges and service agreements by these providers. As of the end of 2025, the company reported an installed base of several thousand Tablo units across the United States. Outset continues to invest in sales and field service personnel to support adoption and maintain high customer satisfaction.